Kornimate/medical-research-clean huggingface dataset:
zinc as enhancer in immune recovery after stem cell transplantation for hematological malignancies

Conditions: Stem Cell Transplant Complications

Summary: patients affected by multiple myeloma undergone autologous stem cell transplantation (sct) are enrolled at the moment of stem cell collection. they are randomized 1:1 in two groups at the moment of the graft. patients of the control group take only standard antimicrobial prophylaxis after sct; the sample group takes in addition a daily oral supplementation of zinc sulfate (600 mg/die) from day +5 until day +100 after sct. laboratory tests are performed on peripheral blood samples.

patients affected by multiple myeloma undergone autologous stem cell transplantation (sct) are enrolled at the moment of stem cell collection. they are randomized 1:1 in two groups at the moment of the graft. patients of the control group take only standard antimicrobial prophylaxis after sct; the sample group takes in addition a daily oral supplementation of zinc sulfate (600 mg/die) from day +5 until day +100 after sct. the aim of the study is to investigate the immune reconstitution in presence of zinc, focused on thymic reconstitution. laboratory tests are performed on peripheral blood samples, collected at 4 time-points: two before transplant (at the moment of the enrollment and the day before conditioning) and two after transplant (day +30 and +100).

Eligibility criteria:
inclusion criteria: * eligibility to stem cell transplantation exclusion criteria: * allergy to zinc * copper deficiency or wilson's syndrome * patients who admit zinc assumption in other drugs

Keywords: zinc
a trial to investigate safety and efficacy of spm927 in painful diabetic neuropathy

Conditions: Painful Diabetic Neuropathy

Summary: the primary purpose is to investigate the safety and efficacy of spm927 in patients with painful diabetic neuropathy


Eligibility criteria:
inclusion criteria: * subject has clinically diagnosed pain attributed to diabetic distal sensory motor polyneuropathy for 1-5 years and a diagnosis of diabetes mellitus (type i or type ii). * subjects must have at least moderate pain (mean pain intensity ≥ 4 out of 10 during the baseline week on likert scale). * subjects must have good or fair diabetic control (hgb a1c \< 10%) exclusion criteria: * subject has other conditions that cause neuropathic pain at least as severe as the diabetic pain i.e. peripheral arterio-vascular disease. * subject receives treatment for seizures. * subject has had any amputations other than diabetically-related toe amputations. * subject has major skin ulcers. * subject has clinically significant ecg abnormalities. * subject is expected to take within 7 days prior to randomization and during the study: tcas, mexiletine hydrochloride, lidoderm patch, tramadol, aeds, dextromethorphan, opioids, capsaicin, nonsteroidal anti-inflammatory drugs, acetaminophen / paracetamol, skeletal muscle relaxants, benzodiazepines, alpha-2-agonists (e.g. clonidine), drugs indicated for sleep disturbance (e. g. zolpidem tartrate, zaleplon) and over-the-counter medications with centrally acting properties. * subject has laboratory values which are outside the normal range and judged by the investigator to be clinically significant. * at study entry, subject has liver function tests values (ast, alt,alkaline phosphatase, total bilirubin and ggt) 2 times upper limit of normal. * subject has impaired renal function, i.e., creatinine clearance is lower than 60 ml/min.

Keywords: lacosamide, vimpat®
comparison of whole body dwi to fdg pet

Conditions: Metastatic Cancer

Summary: this is a single arm prospective trial that evaluates whole body diffusion weight imaging (dwi) compared to 18f-fludeoxyglucose (fdg) positron emission tomography with magnetic resonance imaging (pet/mri) in participants with known metastatic cancer.

primary objective: i. correlation of dwi and fdg to detect disease. secondary objective: i. inter-reader variability of dwi interpretation by region. outline: participants will be imaged at a single timepoint using whole body dwi concurrent with fdg pet/mri within 60 days of receiving a non-fdg pet (either pet/ct or pet/mri). there will be an optional pet/mri performed within six months of the original study. participants will be followed up through a medical records review for up to two years.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. non fdg pet imaging study scheduled to be performed within 60 days (before or after) of the research pet/mri. 3. ability to understand a written informed consent document, and the willingness to sign it. 4. diagnosis of metastatic cancer. exclusion criteria: 1. unlikely to comply with protocol procedures, restrictions and requirements and judged by the investigator to be unsuitable for participation. 2. individuals with contraindications to mri. this will be determined through review of the ucsf mri screening form by qualified site personnel

Keywords: imaging study
quantitative assessment of orofacial muscle function in fshd

Conditions: Facioscapulohumeral Muscular Dystrophy

Summary: the goal of this study is to validate a new method for the assessment of orofacial muscles in fshd affected individuals, using maximal expiratory pressures (meps). our hypothesis is the following: - the pressure drop observed when using circular mouthpieces (versus ovoid mouthpieces) is a reflection of orofacial dysfunction in fshd affected individuals


Eligibility criteria:
inclusion criteria: * genetic diagnosis of fshd type 1 and/or type 2 exclusion criteria: * pregnant women * presence of other associated neuromuscular conditions * any unstable interfering clinical situation
allogeneic human mesenchymal stem cells (hmsc) in patients with aging frailty via intravenous delivery

Conditions: Frailty

Summary: the purpose of this study is to look at the safety of treatment with stem cells in patients with frailty.


Eligibility criteria:
inclusion criteria: * provide written informed consent. * subjects age greater than or equal to 60 and less than or equal to 95 years at the time of signing the informed consent form. * show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 4 to 7 using the clinical frailty scale * female subjects with an follicle-stimulating hormone (fsh) equal to or \> 25.8 milli-international units (miu) /ml (milliliter), if not currently on hormone replacement therapy. exclusion criteria: * score of less than or equal to 24 on the mini mental state examination (mmse) * inability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform pulmonary function tests, undergo blood draws, read and respond to questionnaires. * active listing (or expected future listing) for transplant of any organ. * clinically important abnormal screening laboratory values, including but not limited to: hemoglobin \ 1.5 not due to a reversible cause (i.e. coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase \> 3 times upper limit of normal, total bilirubin \> 1.5 mg/dl. * serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. including, but not limited to: hiv, advanced liver or renal failure, class iii/iv congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect. * any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. * be an organ transplant recipient. * have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma if recurrence occurs. * have a non-pulmonary condition that limits lifespan to \< 1 year. * have a history of drug or alcohol abuse within the past 24 months. * be serum positive for hiv, hepatitis b surface antigen (bsag) or viremic hepatitis c. * be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. * be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion. * have hypersensitivity to dimethyl sulfoxide (dmso)

Keywords: aging frailty frailty cardiovascular stem cells
role of prophylactic tranexamic acid in reducing blood loss during elective caesarean section for placenta praevia major

Conditions: Hemorrhage From Placenta Previa, With Delivery

Summary: prophylactic tranexamic acid will reduce blood loss during caesarean section for placenta praevia

tranexamic acid is a promising agent, easy to administer, cheap, and can be added to the other routine management in hospitals deliveries. this study aims to document the efficacy of intravenous tranexamic acid in reducing blood loss during and after caesarean section in placenta praevia major patients and to assess the hb and platelet change after its administration. general objective: to investigate the effect of prophylactic iv tranexamic acid in reducing blood loss during caesarean section for placenta praevia major specific objectives: 1. to evaluate the effect of prophylactic iv tranexamic acid in reducing blood loss during caesarean section up to 2 hours after caesarean section. 2. to evaluate the drop in haemoglobin level postoperatively with the use of prophylactic iv tranexamic acid for caesarean section for pp major 3. to examine the effect of tranexamic acid on platelet level for caesarean section for pp major 4. to observe the side effects of tranexamic acid this study will be conducted at university kebangsaan malaysia medical centre (ukmmc). patients who meet the inclusion criteria will be invited to participate in the study. patient will be given the information sheet regarding the study and consent will be taken if agreeable to participate. patients' demographic data will be recorded. patients will be classified randomly into two groups using a computer-generated randomization system (microsoft office excel). the list of randomization will be concealed and numbered on sealed opaque envelopes. each number will be given a readily prepared 10ml syringe of colourless solution, which could either contain the tranexamic acid or placebo. each patient will be assigned a serial identification number. the data will be analysed using the statistical package for social sciences (spss).

Eligibility criteria:
inclusion criteria: * all placenta previa major pregnant women exclusion criteria: 1. any cardiac disorder or liver disease 2. patient on anticoagulant therapy 3. history of allergy to tranexamic acid 4. any contraindication for tranexamic acid
understanding visual confusion using stereoscopic displays

Conditions: Diplopia; Binocular Vision Suppression; Binocular; Fusion, With Defective Stereopsis; Monocular Diplopia

Summary: in this research study we want to test how people understand a visual scene when the same image is presented to both the eyes, but portions of these images are altered in terms of contrast, depth or in some cases motion.


Eligibility criteria:
inclusion criteria: * better than 20/40 visual acuity in the worse eye * no restrictions of the peripheral visual field: (at least 60 degrees vertically and 40 degrees horizontally) * at least 14 years of age (no upper age limit) * able to give voluntary, informed consent * able to understand english * binocular vision parameters within normal limits (stereopsis ≤ 100 arc sec on any stereo test) exclusion criteria: * patients with any physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study will be excluded * being unable to complete sessions lasting 2-3 hours

Keywords: visual confusion rivalry head mounted display stereoscopic displays binocular vision
ketogenic diets for symptoms of parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease is a progressive condition that harms nerve cells of the brain (neurodegeneration). current treatments for parkinson's disease (including levodopa and deep brain stimulation) improve certain symptoms but are not thought to improve the underlying neurodegenerative disease process (they are not a "cure"). the cause of parkinson's disease is unknown. however, some evidence suggests that tiny structures in the investigators cells called "mitochondria" might be involved. mitochondria are the powerhouses that produce fuel for the investigators cells. failure of these 'powerhouses' to supply the energy needs of certain nerve cells might lead to parkinson's disease. preliminary evidence suggests that a food called 'ketones' might be able to enhance the function of mitochondria and improve parkinson's disease symptoms and possibly even the neurodegenerative process. in this study, the investigators would like to investigate this possibility by giving patients with parkinson's disease dietary supplements of 'ketone esters' in a drink. the investigators will then assess if this improves symptoms of parkinson's disease. the study design is a prospective, double blinded, randomised, controlled trial.


Eligibility criteria:
inclusion criteria: * patients with primary parkinson's disease fulfilling uk brain bank criteria * age of onset of parkinson's disease symptoms \> 40 years old * duration of symptoms over 2 years exclusion criteria: * dementia * active psychosis * deep brain stimulation or apomorphine infusion * severe motor fluctuations * significant metabolic or uncontrolled medical cormorbidity
effect of helicobacter pylori treatment on idiopathic central serous chorioretinopathy (icscr)

Conditions: Central Serous Chorioretinopathy

Summary: etiology of icscr is not known however recent studies regard the role of immunologic and infectious processes in the pathogenesis of icscr.one of these hypothesis is the role of helicobacter pylori in the pathogenesis of icscr so perhaps treatment of h pylori have positive effect on the remission of icscr.

we will choose 50 cases of patients with icscr who are infected with h.pylori.25 cases will receive anti h.pylori regiment and 25 cases as controls will receive no medication.then we will compare the time of submacular fluid resorption and macular thickness and visual acuity among these two groups.

Eligibility criteria:
inclusion criteria: * the persons who are infected with helicobacter pylori and have icscr exclusion criteria: * history of previous eye surgery ,to have indication of laser therapy,corticosteroid therapy,pregnancy,

Keywords: csr helicobacter pylori
individualizing dual antiplatelet therapy after percutaneous coronary intervention - the ideal-pci registry

Conditions: Platelet Inhibition; Coronary Stent Implantation

Summary: the purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with multiple electrode aggregometry (mea, multiplate® analyzer).

depending on the clinical presentation patients are treated according to standard operating procedures in our department. the earliest, 12 hours after an initial clopidogrel-loading dose (600mg)"on-treatment" platelet reactivity will be determined by multiple electrode aggregometry (mea, multiplate® analyzer), a point of care assay. in case of high residual platelet reactivity (i.e. ≥ 50u), patients are switched according to a therapeutic algorithm to either prasugrel (efient®), or in case of contraindication (i.e. stroke) to ticagrelor (brilique®), or in case of contraindication (intracranial hemorrhage) reloaded with clopidogrel.

Eligibility criteria:
inclusion criteria: * all consecutive pci patients with stent implantation of our institution exclusion criteria: * pregnancy

Keywords: clopidogrel-nonresponder stent thrombosis
the effect of experimental neck pain in healthy participants

Conditions: Healthy; Neck Pain

Summary: this study investigates if/how an experimentally applied muscle pain/soreness, lasting for some days may affect brain activity, balance, movement patterns, muscle function and pain sensitivity in a healthy population

all included healthy volunteers will participate in test-sessions on 4 separate days over approximately 2 weeks. during the study participants will be randomised into and either a control group (injection of isotonic saline into a neck muscle) or neck pain group (injection of nerve growth factor (ngf) into a neck muscle). alle participants tested with regards to: brain activity related to neck muscles will be estimated using tms balance will be tested using a force place body movements will be recorded using 3d tracking muscle activity will be estimated using electromyography (emg)

Eligibility criteria:
inclusion criteria: * healthy men and women aged 18-50 years * only for sub-projects 1 and 2: right-handed * able to speak, read and understand danish and english exclusion criteria: * pain from the neck or shoulder area during the past 6 months * experience of delayed onset muscle soreness (doms) during the week leading up to the test session * former surgery in neck or shoulder * current or previous chronic or recurrent pain condition * pregnancy * drug addiction defined as the use of cannabis, opioids or other drugs * previous neurologic, musculoskeletal or mental illnesses * regular use of analgesics * abnormally disrupted sleep in the last 24 hours preceding the experiment * lack of ability to cooperate * unable to pass the tass safety screening questionnaire for tms
covid 19 preventive measures among mansoura nursing students

Conditions: Covid19

Summary: this study aims to identify nursing students knowledge gaps, risk perceptions and adherence to covid 19 preventive measures during written exam period and in addition due to the possibility of being infected with covid-19 during exams this study will evaluate covid-19 symptoms rate during exam period and factors affecting its development .

as of june,27,2020, egypt lift most covid-19 restrictions and government decided to held written exams for final year students with precautionary measures. students reported fears regarding the possibility of being infected during exams period and want to postpone or cancel exams due to possible contact during transportation and meeting in classes. education have been provided to population in general and students in special through social media, social networks, community leaders to take precautionary measures during exams. studies provide support for the notion of increased vulnerability to respiratory tract infections with exposure to psychological stress . one of specific stress is academic exam stress that has been linked with immuno-suppression. exams are stressful experience and a place for student gathering , moreover there is no research about adherence level or factors affecting adherence to covid-19 precautions among nursing students during exam period. nursing students are future professionals who can address new emerging infectious diseases. the study aims to analyze students adherence to covid 19 preventive measures and to to identify the knowledge gaps, risk perceptions and factors affecting students adherence which could guide the design of better nursing education curricula regarding covid-19 as a preparation for final year nursing students to internship year which will be on september 2020 . in addition due to the possibility of being infected with covid-19 during exams or during their internship year this study will evaluate covid-19 symptoms rate during exam period and factors affecting its development .

Eligibility criteria:
inclusion criteria: * students who agree to participate. * students of both gender . * students who have access to internet and have whatsapp account exclusion criteria: * students diagnosed with covid-19 before.

Keywords: covid 19 preventive measures nursing students
automated connective tissue torque sensor

Conditions: Connective Tissue; Musculoskeletal Pain

Summary: the purpose of this study is to develop a measure - the needle torque test - capable of detecting connective tissue abnormalities associated with musculoskeletal disorders.

chronic musculoskeletal pain is a source of considerable disability, work absenteeism and health care costs. a major obstacle to the treatment of these conditions is the lack of methods to objectively assess connective tissues and measure the effect of treatments. needle torque test technology under development in this project will potentially enable objective measurement of connective tissue abnormalities associated with musculoskeletal pain and dysfunction. this could help evaluate the efficacy of various treatments and enhance the objective monitoring of patient progress in clinical practice.

Eligibility criteria:
inclusion criteria for chronic low back pain subjects: * back pain that has disrupted activity for more than half the days in the past 12 months. inclusion criteria for restricted hamstring subjects: * 90/90 test of more than 20 degrees inclusion criteria for systemic scleroderma subjects: * physician diagnosis inclusion criteria for joint hyperlaxity subjects: * beighton test score of 7 or higher exclusion criteria for all subjects: * surgery or scars in thighs or low back * neurological or major psychiatric disorder * bleeding disorders * acute systemic infection * pregnancy
better disease control by multidrug regimen in scabies

Conditions: Scabies

Summary: scabies is associated with significant discomfort and social taboo. existing treatment regimen frequently fails due to lack of patient compliance. we compared single use regimen to existing standard repeat application regimen for treatment of scabies.


Eligibility criteria:
inclusion criteria: * willing patients * clinical diagnosis of scabies * within the age limits exclusion criteria: * unwilling patients * patients with severe co-morbidities requiring long term medication * pregnant women * patients who don't fulfill the age limit criteria

Keywords: scabies permethrin ivermectin combination regimen